Catalyst4, Inc. bought MLPT
August 14, 2026 · Form 4 insider transaction
Catalyst4, Inc. bought 2,928,686 shares of MapLight Therapeutics, Inc. at $11.38 per share, a transaction worth $33.33M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
The warrant is immediately exercisable, however, the warrant may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the reporting person immediately following such exercise would exceed 49.99%.; The warrants will not expire until exercised in full.; The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.